This study is not yet accepting patients
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSD UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Kara Chew, MD, MS (ucla)

Description
Summary
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Kara Chew, MD, MS (ucla)
Associate Professor-in-residence, Medicine. Authored (or co-authored) 85 research publications
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- ID
- NCT06680479
- Phase
- Phase 1 HIV/AIDS Research Study
- Study Type
- Interventional
- Participants
- Expecting 30 study participants
- Last Updated